11 completed, 1 terminated, 1 unknown. 13 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 11, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Dermatitis, Seborrheic: new trials by email Literature Review of Dermatitis, Seborrheic trials Research Report on Dermatitis, Seborrheic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea PF-07038124, Placebo Ointment - Seborrheic Dermatitis, Papulopustular Rosacea | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 32 | 2023-07-19 | 2026-08-14 |
| Ruxolitinib in Seborrheic Dermatitis Ruxolitinib 1.5% Cream - Seborrheic Dermatitis | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 45 | 2022-11-15 | 2025-05-06 |
| Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis ARQ-154 - Seborrheic Dermatitis | Phase 2 | Completed | Arcutis Biotherapeutics, Inc. | 408 | 2020-06-12 | 2024-06-11 |
| Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis Roflumilast Foam 0.3%, Vehicle foam - Seborrheic Dermatitis | Phase 2 | Completed | Arcutis Biotherapeutics, Inc. | 226 | 2019-12-04 | 2023-07-03 |
| Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult Natural Treatment - Dermatitis, Seborrheic, Dry Skin; Eczema | Phase 1 / Phase 2 | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 77 | 2019-07-08 | 2025-02-24 |
| Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis Omiganan, Ketoconazole, Placebo - Seborrheic Dermatitis | Phase 2 | Unknown | Maruho Co., Ltd. | 36 | 2018-10-22 | 2019-05-01 |
| A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease Cannabidiol, Placebo - Parkinson Disease | Phase 2 | Completed | University of Colorado, Denver | 74 | 2018-09-05 | 2024-07-23 |
| A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis PAC-14028 cream 0.3%, PAC-14028 cream 1.0%, PAC-14028 cream vehicle - Seborrheic Dermatitis | Phase 2 | Completed | Amorepacific Corporation | 75 | 2014-02-01 | 2016-04-25 |
| Safety and Efficacy Study in Subjects With Seborrheic Dermatitis Test Product 49778, Test Product 10156, Vehicle (placebo) - Seborrheic Dermatitis | Phase 2 | Completed | Medicis Global Service Corporation | 240 | 2012-09-01 | 2013-01-09 |
| Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers MTC896 Gel - Oily Skin, Seborrhea | Phase 2 | Completed | Mimetica Pty Limited | 135 | 2010-07-01 | 2014-09-12 |
| The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage Topical oxygen, placebo - Rosacea, Acne Vulgaris | Phase 2 | Completed | Aria Aesthetics Inc. | 49 | 2009-09-01 | 2011-06-08 |
| A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis Elidel, Ketoconazole Cream - Seborrheic Dermatitis | Phase 2 | Completed | Dermatology Specialists Research | 113 | 2007-05-07 | 2022-03-14 |
| Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp K40a, K40b, Placebo - Seborrhoeic Dermatitis of the Scalp | Phase 2 / Phase 3 | Completed | Moberg Pharma AB | 98 | 2007-02-01 | 2010-06-04 |
Rosacea (2) · Acne Vulgaris (1) · Anxiety Disorders (1) · Dermatitis, Atopic (1) · Dyskinesias (1) · Eczema (1) · Marijuana Abuse (1) · Parkinson Disease (1) · Psychotic Disorders (1) · Tremor (1)
Dermatitis (13) · Sebaceous Gland Diseases (13) · Skin Diseases (13) · Skin Diseases, Eczematous (13) · Skin Diseases, Papulosquamous (13) · Skin and Connective Tissue Diseases (13) · Acneiform Eruptions (1) · Basal Ganglia Diseases (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Chemically-Induced Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1)
Ketoconazole (2) · Cannabidiol (1) · Omiganan (1) · Oxygen (1) · pimecrolimus (1) · ruxolitinib (1)
Arcutis Biotherapeutics, Inc. (2) · Icahn School of Medicine at Mount Sinai (2) · Amorepacific Corporation (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Aria Aesthetics Inc. (1) · Dermatology Specialists Research (1) · Maruho Co., Ltd. (1) · Medicis Global Service Corporation (1) · Mimetica Pty Limited (1) · Moberg Pharma AB (1) · University of Colorado, Denver (1)
United States (10) · Canada (1) · Netherlands (1) · Sweden (1)
Benjamin Ungar, MD (2) · David Berk, MD (2) · BeomJoon Kim, Professor (1) · Bernard Goffe, MD (1) · Debra Breneman, MD (1) · Ira Lawrence, MD (1) · Jonathan S Dosik, MD (1) · Lennart Emtestam, MD (1) · Lucy Bilaver, PHD (1) · Maureen Leehey (1) · Robert Rissmann, PhD (1) · Steven Kempers, MD (1) · Zoe D Draelos, MD (1)